title: Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.
abstract: Hepatitis C virus (HCV) subtype 1b, which infects approximately 70% of Japanese carriers, is likely to be more eradicable by a telaprevir regimen than subtype 1a because of the higher genetic barrier of Val(36) and Arg(155) substitutions. The aims of this exploratory study were to evaluate the virological response and safety of 24-week oral administration of telaprevir alone in chronic HCV subtype 1b infection. Fifteen treatment-naïve patients were treated with telaprevir 750 mg every 8 h for 24 weeks. All patients were Japanese whose median age was 58.0 years (range: 45-68), and six patients (40%) were men. Median baseline HCV RNA level was 6.80 log(10) IU/mL (range: 3.55-7.10). The HCV RNA levels decreased to undetectable in five patients (33%) within 8 weeks. Three patients (20%) with negative HCV RNA by Week 4 achieved end of treatment response. One patient (7%) who achieved sustained virological response had a low baseline viraemia of 3.55 log(10) IU/mL. Most of the adverse events including anaemia and skin disorders were mild to moderate. Developed variants were T54A and A156V/T/F/Y with or without secondary substitutions rather than V36M ± R155K. Telaprevir alone for 24 weeks in Japanese patients with HCV subtype 1b resulted in an sustained viral response rate of 7% (1/15) and was well tolerated for 24 weeks. These results will support the implementation of further studies on oral combination of telaprevir with other direct-acting antiviral agents in patients infected with HCV subtype 1b.
authors: Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan. joji.toyota@ja-hokkaidoukouseiren.or.jp
authors: J
authors: J
authors: Toyota
authors: I
authors: I
authors: Ozeki
authors: Y
authors: Y
authors: Karino
authors: Y
authors: Y
authors: Asahina
authors: N
authors: N
authors: Izumi
authors: S
authors: S
authors: Takahashi
authors: Y
authors: Y
authors: Kawakami
authors: K
authors: K
authors: Chayama
authors: N
authors: N
authors: Kamiya
authors: K
authors: K
authors: Aoki
authors: I
authors: I
authors: Yamada
authors: Y
authors: Y
authors: Suzuki
authors: F
authors: F
authors: Suzuki
authors: H
authors: H
authors: Kumada
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000473:pathology; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects*; D012367:RNA, Viral / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load; D014764:Viral Proteins / Q000235:genetics
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D012367:RNA, Viral; D014764:Viral Proteins; C486464:telaprevir
references: J Hepatol. 2011 May;54(5):872-8
references: 21145818
references: Hepatology. 2008 Dec;48(6):1769-78
references: 19026009
references: N Engl J Med. 2009 Apr 30;360(18):1839-50
references: 19403903
references: N Engl J Med. 2010 Apr 8;362(14):1292-303
references: 20375406
references: J Biol Chem. 2005 Nov 4;280(44):36784-91
references: 16087668
references: Hepatology. 2012 Mar;55(3):742-8
references: 21987462
references: Intervirology. 1994;37(2):68-76
references: 7814244
references: J Hepatol. 2011 Apr;54(4):604-11
references: 21145907
references: Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):20986-91
references: 21084633
references: J Gastroenterol. 2011 Jul;46(7):929-37
references: 21556829
references: Gastroenterology. 2007 May;132(5):1767-77
references: 17484874
references: J Viral Hepat. 2012 Feb;19(2):e112-9
references: 22239508
references: Gastroenterology. 2011 Feb;140(2):667-75
references: 21056040
references: Antimicrob Agents Chemother. 2008 Jan;52(1):110-20
references: 17938182
references: N Engl J Med. 2011 Jun 23;364(25):2405-16
references: 21696307
references: Gastroenterology. 2010 Feb;138(2):447-62
references: 20006612
references: N Engl J Med. 2009 Apr 30;360(18):1827-38
references: 19403902
references: Gut. 2006 Sep;55(9):1350-9
references: 16905701
references: N Engl J Med. 2012 Jan 19;366(3):216-24
references: 22256805
references: J Infect Dis. 2010 Mar;201(5):751-9
references: 20102281
references: N Engl J Med. 2011 Jun 23;364(25):2417-28
references: 21696308
references: J Clin Virol. 2010 Jan;47(1):76-8
references: 19857995
references: J Hepatol. 2012 Jan;56(1):78-84
references: 21827730
references: J Viral Hepat. 2012 Feb;19(2):e134-42
references: 22239511
references: Hepatology. 2007 Sep;46(3):631-9
references: 17680654
references: Intervirology. 2010;53(1):39-43
references: 20068339
references: N Engl J Med. 2011 Sep 15;365(11):1014-24
references: 21916639